Adherence, quality of life, and general satisfaction with co-formulated zidovudine, lamivudine, and abacavir on antiretroviral-experienced patients

HIV Clinical Trials

Volumn 5, Issue 1, 2004, Pages 33-39

  Clotet, Bonaventura ^a   Carmena, Jorge ^b   Pulido, Federico ^c   Luque, Isabel ^d   Rodriguez Alcántara, Felipe ^d   Hernandez Quero, Jose ^e   Knobel, Hernando ^f   Lopez Aldeguer, José ^g   Maradona, José Antonio ^h   Masabeu, Angeles ⁱ   Pedrol, Enric ^j   Portilla, Joaquín ^k   Ribera, Esteban ^l   Santos, Jesús ^m   Téllez, María Jesús ⁿ   Trapiella, Luis ^o   Villaverde, Carlos Alonso ^p  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d GLAXOSMITHKLINE   (Spain)

^e HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^f HOSPITAL DEL MAR   (Spain)

^g HOSPITAL UNIVERSITARIO LA FE   (Spain)

^h Department of Vascular Surgery   (Spain)

ⁱ Hospital de Palamos   (Spain)

^j Manresa General Hospital   (Spain)

^k GENERAL HOSPITAL   (Spain)

^l HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^m HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

ⁿ HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^o HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^p HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

more..

Author keywords

Abacavir; Adherence; General satisfaction; HIV; Lamivudine; Lipids; Quality of life; Zidovudine

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; CHOLESTEROL; LAMIVUDINE; TRIACYLGLYCEROL; ZIDOVUDINE;

ADULT; ARTICLE; BACTERIAL INFECTION; BIOCHEMISTRY; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG SAFETY; DRUG USE; GASTROINTESTINAL DISEASE; HEMATOLOGIC DISEASE; HEMATOLOGICAL PARAMETERS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PATIENT SATISFACTION; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RESPIRATORY TRACT DISEASE; SELF REPORT; SKIN DISEASE; STATISTICAL ANALYSIS; TRIACYLGLYCEROL BLOOD LEVEL; URINARY TRACT DISEASE; VIRUS INFECTION; VIRUS LOAD; VISUAL ANALOG SCALE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; ANTI-RETROVIRAL AGENTS; ANTIGENS, CD4; DIDEOXYNUCLEOSIDES; FEMALE; HUMANS; LAMIVUDINE; MALE; PATIENT COMPLIANCE; PATIENT SATISFACTION; QUALITY OF LIFE; QUESTIONNAIRES; ZIDOVUDINE;

EID: 12144288676     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/J8N0-8QCF-GDBA-0F22     Document Type: Article

References (17)

1. Hammer SM, Squires K, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med. 1997;337(11):725-733.
2. García de Olalla P, Knobel H, Carmona A, et al. Impact of adherence and highly active antiretroviral therapy on survival in HIV infected patients. J Acquir Immume Defic Syndr. 2002;30(1):105-110.
3. Stone VE, Hogan JW, Schuman P, et al. Antiretroviral regimen complexity, self-reported adherence, and HIV patients' understanding of their regimens: A survey of women in the HER study. J Acquir Immune Defic Syndr. 2001;28(2):124-131.
4. Tebas P, Royal M, Fichtenbaum C, et al. Relationship between adherence to HAART and disease state. Poster presented at: Fifth Conference on Retroviruses and Opportunistic Infections; February 1998; Chicago. Session 24.
5. Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med. 1999;341:1865-1873.
6. Gordillo V, Amo J, Soriano V, et al. Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS. 1999;13:1763-1769.
7. Stone VE. Strategies for optimizing adherence to highly active antiretroviral therapy: Lessons from research and clinical practice. Clin Infect Dis. 2001;93:865-872.
8. Wu AW, Hays RD, Malitz F, Bozette SA. Applications of the Medical Outcomes Study health-related quality of life measures in HIV/AIDS. Qual Life Res. 1997;531-554.
9. Rosendorf LL, Dafni U, Amato DA, et al. Performance evolution in multicenter clinical trials: Development of a model by the AIDS Clinical Trials Group. Control Clin Trials. 1993;14(6):523-537.
10. Gourevitch MN, Friedlan GH. Interactions between methadone and medication used to treat HIV infection: A review. Mount Sinai J Med. 2000;67:429-436.
11. Danner SA, Carr A, Leonard JM, et al. A short term study of the safety pharmacokinetics and efficacy of ritonavir, an inhibitor of HIV-1 pratease. N Engl J Med. 1995;333:1528-1533.
12. Sullivan AK, Nelson MR. Marked hyperlipidemia on ritonavir therapy. AIDS. 1998;12(11):1393-1394.
13. Carr A, Smaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin due to HIV protease inhibitors. AIDS. 1998;2:F51-58.
14. Martinez E, Conget I, Lozano L, et al. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS. 1999;13:805-810.
15. Ruiz L, Negredo, E, Domingo P, et al. Clinical, virological, and immunological benefit of switching from HIV-1 protease inhibitors to nevirapine in HAART-experienced patients suffering lipodystrophy: 36-week follow-up [abstract 206]: Proceedings of the Seventh Conference on Retroviruses and Opportunistic Infections, San Francisco, CA. Alexandria, VA: Foundation for Retrovirology and Human Health; 2000:114.
16. Tebas P, Yarasheski K, Powderly WG, et al. A prospective, open-label pilot trial of a maintenance nevirapine-containing regimen in patients with undetectable viral loads on protease inhibitor regimens for at least 6 months [abstract 45]: Proceedings of the Seventh Conference on Retroviruses and Opportunistic Infections, San Francisco, CA. Alexandria, VA: Foundation for Retrovirology and Human Health; 2000:83.
17. Bonnet E, Lepec R, Bluteau M, et al. Evolution of lipodystrophy syndrome and lipidic profile in HIV patients after switching from protease inhibitors to efavirenz [abstract 49]: Proceedings of the Seventh Conference on Retroviruses and Opportunistic Infections, San Francisco, CA. Alexandria, VA: Foundation for Retrovirollogy and Human Health; 2000:84.